title: Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
abstract: The effect of 12 and 24 h continuous subcutaneous infusion of desferrioxamine (D.F.) on urinary iron excretion was compared in 13 patients with beta-thalassaemia major and 1 with congenital sideroblastic anaemia, all of whom were receiving regular blood-transfusions. 750 mg D.F. given over a 12 h period, gave a mean total (30 h) iron excretion of 17-5 mg, which was not statistically different from the mean iron excretion of 21-5 mg when the same dose was delivered over 24 h. 1500 mg D.F. gave a mean urinary iron excretion of 28-1 mg with a 12 h infusion, which was significantly less than the mean iron excretion of 39-6 mg with 24 h infusion. The 1500 mg dose gave a significant increase in iron excretion compared with the 750 mg dose when given by either 12 h or 24 h infusion. 7 of 8 patients, given D.F. over a 12 h period, had increased iron excretion when the dose was increased from 750 to 2000 mg. When the dose was increased to 4000 mg, however, the effect on iron excretion was variable. On the other hand, ascorbic-acid therapy was invariably associated with increased iron excretion after subcutaneous D.F. In twelve studies at different dose levels of D.F., ascorbate therapy was associated with increased iron excretion ranging from 24 to 245%. It is concluded that in most patients with transfusional iron overload subcutaneous D.F over a 12 h period, at a dose ranging from 2 to 4 g daily with ascorbic-acid saturation, is at present the most satisfactory method of removing excess iron.
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000756:Anemia, Sideroblastic / Q000151:congenital / Q000628:therapy; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000652:urine*; D008297:Male; D012867:Skin; D013789:Thalassemia / Q000628:therapy; D065227:Transfusion Reaction
chemical_list: D007501:Iron; D003676:Deferoxamine; D001205:Ascorbic Acid